Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON30737
NL-OMON30737
Not yet recruiting
Not Applicable

A multi-center, single arm, prospective study of the WallFlex biliary partially covered stent for the palliative treatment of malignant bile duct obstruction. - WallFlex Biliary PC Study

Boston Scientific Corporation0 sites18 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMalignant biliary obstructionmalignant obstruction of the biliary tract10019815

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Malignant biliary obstruction
Sponsor
Boston Scientific Corporation
Enrollment
18
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Inoperable extrahepatic biliary obstruction by any malignant process.
  • •Indicated for metal stent placement for palliative treatment of biliary stricture(s) produced by malignant neoplasms.

Exclusion Criteria

  • •Strictures that cannot be dilated enough to pass the delivery system.
  • •Perforation of any duct within the biliary tree.
  • •Presence of metal biliary stent.
  • •Patients with active hepatitis.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
SPECTACLE studyRectal cancer
JPRN-jRCTs032230212Watanabe Jun400
Completed
Not Applicable
A prospective, multi-center, single-arm study of tOCP/Col for guided bone regeneratiobone defect
JPRN-UMIN000018192TOYOBO CO., LTD.60
Withdrawn
Phase 3
A Prospective, Multi-Center, Single Arm Study of the Conor Cobalt Chromium Reservoir Based Stent (Nevo) with Sirolimus Elution in Native Coronary Artery Lesions (CP-07 protocol)
NL-OMON32462Conor Medsystems, LLC (maakt deel uit van Johnson & Johnson); contact persoon Emily Hergenreter40
Completed
Not Applicable
OFT-G1-301 StudyCongenital heart disease
JPRN-jRCT1080224691TEIJIN LIMITED / TEIJIN PHARMA LIMITED30
Not yet recruiting
Phase 4
The aim is to evaluate the safety and efficacy of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold in coronary artery disease patients.It enhances coronary luminal diameter in symptomatic ischemic heart disease, addressing de novo lesions in native coronary arteries.Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
CTRI/2024/02/062438Meril Diagnostics Private Limited